The Belgian pharma is buying a two-year-old San Diego biotech for $2bn upfront, the second TCE bet it has placed in months. The thesis: B-cell killers built for cancer can rewire how autoimmune diseases are treated. Candid Therapeutics is two years old. It does not have an approved drug. Its lead programme has been tested […]<br /> This story continues at The Next Web [...]
Tinny music plays in a dimly lit basement as we watch a teenager pull football shirts off a nearby clothing rack and hold them up to the camera. He describes each item monotonously — the team, season, colour, and condition — before sticking on a numbered label and transferring them to another rack. Each item gets less than a minute in the limelight. Bid rates and prices are listed at the botto [...]